Wedzicha J A
Academic Department of Respiratory Medicine, St Bartholomew's and Royal London School of Medicine and Dentistry, St Bartholomew's Hospital, UK.
Respir Care. 2000 Feb;45(2):178-85; discussion 186-7.
The use of positive-pressure nasal ventilation in combination with LTOT in stable COPD patients with hypercapnic respiratory failure controls hypoventilation and improves daytime ABGs, sleep, and quality of life. Nasal ventilation in COPD is unlikely to produce benefit unless used with supplemental oxygen therapy at night. The patients who show the greatest reduction in overnight PaCO2 with ventilation are the patients most likely to benefit from long-term ventilatory support. Although there is now evidence for short-term benefit from NPPV in hypercapnic COPD, large multicenter studies with survival, exacerbations, and hospital admissions as the primary end points are required to evaluate longer-term effects of this potentially important intervention.
在伴有高碳酸血症呼吸衰竭的稳定期慢性阻塞性肺疾病(COPD)患者中,使用正压鼻通气联合长期氧疗(LTOT)可控制通气不足,并改善日间动脉血气(ABGs)、睡眠及生活质量。在COPD患者中,鼻通气不太可能产生益处,除非在夜间与补充氧气疗法联合使用。夜间通气时PaCO₂降低幅度最大的患者最有可能从长期通气支持中获益。尽管目前有证据表明无创正压通气(NPPV)对高碳酸血症型COPD有短期益处,但仍需要以生存、急性加重和住院作为主要终点的大型多中心研究来评估这种潜在重要干预措施的长期效果。